Explore the words cloud of the EBOVAC1 project. It provides you a very rough idea of what is the project "EBOVAC1" about.
The following table provides information about the project.
LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER
|Coordinator Country||United Kingdom [UK]|
|Total cost||98˙044˙689 €|
|EC max contribution||58˙336˙885 € (60%)|
1. H2020-EU.220.127.116.11. (Other)
|Duration (year-month-day)||from 2014-12-01 to 2021-11-30|
Take a look of project's partnership.
|1||LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER||UK (LONDON)||coordinator||44˙720˙692.00|
|2||UNIVERSITY OF SIERRA LEONE||SL (FREETOWN)||participant||11˙524˙564.00|
|3||THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD||UK (OXFORD)||participant||1˙437˙905.00|
|4||INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE||FR (PARIS)||participant||653˙722.00|
|5||JANSSEN VACCINES & PREVENTION BV||NL (LEIDEN)||participant||0.00|
The overall aim of the EBOVAC programme is to assess the safety and efficacy of a novel prime boost prophylactic vaccine regimen against Ebola Virus Disease (EVD), which has been 100% effective in preclinical studies. This will be done via phase I, II and III trials carried out in the EU and in Africa, in response to the urgent public health need raised by the current Ebola epidemic. To expedite the development of the vaccine regimen, Phase II and Phase III trials will be carried out in parallel and therefore co-ordinated by two separate teams. Proposals responding to IMI2 Topic 1 will consequently be split into two parts. EBOVAC1 will address the Phase I and Phase III trials, whereas EBOVAC2 will address the Phase II trials.
EBOVAC1 will establish the initial safety and immunogenicity of the proposed heterologous prime/ boost regimen of Ad26.ZEBOV and MVA-BNFilo vaccine through phase I studies conducted in the UK, the US and currently Ebola- unaffected African countries. This will be done by administering the vaccine in different sequences and at different time intervals so as to identify the shortest schedule that is immunogenic and to maximize the potential for short term efficacy in affected countries. Initiation of these trials is expected to occur between December 2014 and March 2015 and approximately 300 subjects will be enrolled.
The main objective therefore of EBOVAC 2 is to provide extensive and robust data on the safety, immunogenicity and efficacy of the Ad26.ZEBOV and MVA-BN-Filo vaccine.
This will be done by:
1. Carrying out translational studies to link vaccine elicited immune responses in humans to protection from Ebola in vaccinated non-human primates (via WP4) 2. Carrying out Phase II trials in African and European volunteers in 6 countries, four in Africa and two in the EU with an overall target enrolment of approximately 1,500 subjects. Given the compressed nature of this development program, the Phase II studies will be conducted in parallel
|Publish Information Governance Policy||Documents, reports||2019-04-02 13:36:04|
Take a look to the deliverables list in detail: detailed list of EBOVAC1 deliverables.
|year||authors and title||journal||last update|
ChloÃ© Pasin, Irene Balelli, Thierry Van Effelterre, Viki Bockstal, Laura Solforosi, MÃ©lanie Prague, Macaya Douoguih, Rodolphe ThiÃ©baut
Dynamics of the Humoral Immune Response to a Prime-Boost Ebola Vaccine: Quantification and Sources of Variation
published pages: , ISSN: 0022-538X, DOI: 10.1128/jvi.00579-19
|Journal of Virology 93/18||2020-03-05|
Mario Jendrossek, W. John Edmunds, Hana Rohan, Samuel Clifford, Thomas A. Mooney, Rosalind M. Eggo
Health care worker vaccination against Ebola: Vaccine acceptance and employment duration in Sierra Leone
published pages: 1101-1108, ISSN: 0264-410X, DOI: 10.1016/j.vaccine.2018.12.060
Alexis Robert, W John Edmunds, Conall H Watson, Ana Maria Henao-Restrepo, Pierre-StÃ©phane Gsell, Elizabeth Williamson, Ira M Longini, KeÃ¯ta Sakoba, Adam J Kucharski, Alhassane TourÃ©, SÃ©vÃ©rine Danmadji Nadlaou, Boubacar Diallo, Mamamdou Saidou Barry, Thierno Oumar Fofana, Louceny Camara, Ibrahima Lansana Kaba, Lansana Sylla, Mohamed Lamine Diaby, Ousmane Soumah, Abdourahime Diallo, Amadou Niar
Determinants of Transmission Risk During the Late Stage of the West African Ebola Epidemic
published pages: 1319-1327, ISSN: 0002-9262, DOI: 10.1093/aje/kwz090
|American Journal of Epidemiology 188/7||2020-03-05|
Zacchaeus Anywaine, Hilary Whitworth, Pontiano Kaleebu, George Praygod, Georgi Shukarev, Daniela Manno, Saidi Kapiga, Heiner Grosskurth, Samuel Kalluvya, Viki Bockstal, Dickson Anumendem, Kerstin Luhn, Cynthia Robinson, Macaya Douoguih, Deborah Watson-Jones
Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania
published pages: 46-56, ISSN: 0022-1899, DOI: 10.1093/infdis/jiz070
|The Journal of Infectious Diseases 220/1||2020-03-05|
Alexis Robert, Anton Camacho, W. John Edmunds, Marc Baguelin, Jean-Jacques Muyembe Tamfum, Alicia Rosello, Sakoba KÃ©Ã¯ta, Rosalind M. Eggo
Control of Ebola virus disease outbreaks: Comparison of health care worker-targeted and community vaccination strategies
published pages: 106-114, ISSN: 1755-4365, DOI: 10.1016/j.epidem.2019.03.001
Gaudensia Mutua, Omu Anzala, Kerstin Luhn, Cynthia Robinson, Viki Bockstal, Dickson Anumendem, Macaya Douoguih
Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya
published pages: 57-67, ISSN: 0022-1899, DOI: 10.1093/infdis/jiz071
|The Journal of Infectious Diseases 220/1||2020-03-05|
Anton Camacho, Rosalind M Eggo, Sebastian Funk, Conall H Watson, Adam J Kucharski, W John Edmunds
Estimating the probability of demonstrating vaccine efficacy in the declining Ebola epidemic: a Bayesian modelling approach
published pages: e009346, ISSN: 2044-6055, DOI: 10.1136/bmjopen-2015-009346
|BMJ Open 5/12||2019-05-15|
An Vandebosch, Robin Mogg, Nele Goeyvaerts, Carla Truyers, Brian Greenwood, Debby Watson-Jones, Guillermo Herrera-Taracena, Wim Parys, Tony Vangeneugden
Simulation-guided phase 3 trial design to evaluate vaccine effectiveness to prevent Ebola virus disease infection: Statistical considerations, design rationale, and challenges
published pages: 57-65, ISSN: 1740-7745, DOI: 10.1177/1740774515621059
|Clinical Trials: Journal of the Society for Clinical Trials 13/1||2019-05-15|
Rosalind M Eggo, Conall H Watson, Anton Camacho, Adam J Kucharski, Sebastian Funk, W John Edmunds
Duration of Ebola virus RNA persistence in semen of survivors: population-level estimates and projections
published pages: Volume 20, 2015, ISSN: 1025-496X, DOI: 10.2807/1560-7917.ES.2015.20.48.30083
Adam J. Kucharski, Rosalind M. Eggo, Conall H. Watson, Anton Camacho, Sebastian Funk, W. John Edmunds
Effectiveness of Ring Vaccination as Control Strategy for Ebola Virus Disease
published pages: 105-108, ISSN: 1080-6040, DOI: 10.3201/eid2201.151410
|Emerging Infectious Diseases 22/1||2019-05-15|
Rebecca L. Winslow, Iain D. Milligan, Merryn Voysey, Kerstin Luhn, Georgi Shukarev, Macaya Douoguih, Matthew D. Snape
Immune Responses to Novel Adenovirus Type 26 and Modified Vaccinia Virus Ankaraâ€“Vectored Ebola Vaccines at 1 Year
published pages: 1075, ISSN: 0098-7484, DOI: 10.1001/jama.2016.20644
Martinus A.H. Capelle, Lara Babich, J.P. Els van Deventer-Troost, Doris Salerno, Kelly Krijgsman, Ulrike Dirmeier, Britt Raaby, Janik Adriaansen
Stability and suitability for storage and distribution of Ad26.ZEBOV/MVA-BNÂ®-Filo heterologous prime-boost Ebola vaccine
published pages: 215-221, ISSN: 0939-6411, DOI: 10.1016/j.ejpb.2018.06.001
|European Journal of Pharmaceutics and Biopharmaceutics 129||2019-04-18|
Luisa Enria, Shelley Lees
Citizens, dependents, sons of the soil: Defining political subjectivities through encounters with biomedicine during the Ebola epidemic in Sierra Leone
published pages: , ISSN: 2405-691X, DOI: 10.17157/mat.5.4.512
|Medicine Anthropology Theory | An open-access journal in the anthropology of health, illness, and medicine 5/4||2019-04-18|
Angus Fayia Tengbeh, Luisa Enria, Elizabeth Smout, Thomas Mooney, Mike Callaghan, David Ishola, Bailah Leigh, Deborah Watson-Jones, Brian Greenwood, Heidi Larson, Shelley Lees
â€œWe are the heroes because we are ready to die for this countryâ€: Participants\' decision-making and grounded ethics in an Ebola vaccine clinical trial
published pages: 35-42, ISSN: 0277-9536, DOI: 10.1016/j.socscimed.2018.03.008
|Social Science & Medicine 203||2019-04-18|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EBOVAC1" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "EBOVAC1" are provided by the European Opendata Portal: CORDIS opendata.
Development of a Prophylactic Ebola Vaccine Using an Heterologous Prime-Boost Regimen – Sofia ref.: 115854Read More
Vaccine safety and immunogenicity signatures of human responses to VSV-ZEBOV – Sofia ref.: 115842Read More
Accelerated Development of Appropriate Patient Therapies: a Sustainable, Multi-stakeholder Approach from Research to Treatment-outcomes - Sofia ref.: 115890Read More